{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    8,
    17,
    19,
    20,
    23,
    185,
    190,
    191,
    192
  ],
  "modelUsed": "gemini-3-flash-preview",
  "advanced": {
    "studyAmendments": [
      {
        "id": "amend_1",
        "number": "5",
        "name": "Amendment 5",
        "scope": {
          "id": "44a54f5e-a64e-4bac-af04-866147fc76c6",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "cbe37e83-323d-4467-a982-490aa1e36dbd",
          "code": {
            "id": "fc0cc72c-4421-4984-bd2a-729c474f3e6a",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "4e74d3db-fad4-4f0d-8521-6a38921f9cb4",
            "type": {
              "id": "219ac0ea-2181-4189-8448-2f72efda0f34",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The protocol is amended with the following main changes: Addition of statistical testing for some secondary efficacy endpoints; Addition of an exit interview for participants from selected countries.",
        "effectiveDate": "2021-08-20",
        "reasonIds": [
          "ar_1_1",
          "ar_1_2",
          "ar_1_3"
        ],
        "previousVersion": "Amended Clinical Trial Protocol 04",
        "newVersion": "1 (electronic 7.0)"
      },
      {
        "id": "amend_2",
        "number": "4",
        "name": "Amendment 4",
        "scope": {
          "id": "fb6ce318-cf38-4d50-9c21-39210cdf0337",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "3d5ea74f-9745-484a-841c-38a9316046ed",
          "code": {
            "id": "1ecc8928-205f-4b18-ac46-6c84a16cc593",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "6a51db37-9d24-4d02-9749-c0256c02f2dd",
            "type": {
              "id": "c6b48d45-9e11-4157-9ae8-f1c45814044d",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The main reasons for this amendment are the following: to modify the requirements for the washout of FVIII products before screening and allow inclusion of patients based on historical FVIII results or documented genotype known to produce severe hemophilia A; to allow for flexibility in the washout of FVIII products before the Baseline visit in patients participating in the abbreviated PK group; to allow for faster infusion rate for the BIVV001 injection performed at home; to clarify that in case of minor surgery the FVIII activity and the BIVV001 dosing at the 24h follow up will be performed only if clinically warranted; to clarify the reporting of overdoses; to clarify that during study visits, for reliable PK assessment, PK sampling should not be done via the same intravenous access route as used for the BIVV001 administration.",
        "effectiveDate": "2020-05-13",
        "reasonIds": [
          "ar_2_1",
          "ar_2_2",
          "ar_2_3"
        ],
        "previousVersion": "Amended Clinical Trial Protocol 03",
        "newVersion": "1 (electronic 5.0)"
      },
      {
        "id": "amend_3",
        "number": "3",
        "name": "Amendment 3",
        "scope": {
          "id": "4e51ff93-c229-4b09-be23-73eee757b3d8",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "f32aeb3e-bfc5-4313-bdf7-b3ac81efc53e",
          "code": {
            "id": "8b7d304f-26f3-4695-ad9b-fc170d15eab7",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "147acbc4-d6fe-47a9-a5b1-59b5a05a07a4",
            "type": {
              "id": "ea78aeec-57a5-42fb-8cce-2c00e9cef12e",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "Based on the request from Italy Competent Authority (AIFA) the protocol is amended to update an exclusion criterion related to renal function, as well as to add additional assessments for height and physical examination.",
        "effectiveDate": "2020-04-06",
        "reasonIds": [
          "ar_3_1"
        ],
        "previousVersion": "Amended Clinical Trial Protocol 02",
        "newVersion": "1 (electronic 4.0)"
      },
      {
        "id": "amend_4",
        "number": "2",
        "name": "Amendment 2",
        "scope": {
          "id": "2a8a8618-76dc-41cc-9c6d-5d0004baa4f8",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "5ea71f21-1d09-425e-8fae-5194416bdbb3",
          "code": {
            "id": "81a6c5ef-2a01-4885-953a-9a516cdeb4c6",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "32bda8ab-099b-452e-9617-6a6d2338691b",
            "type": {
              "id": "9157b378-f5c4-4949-b791-31a70d7b1eef",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "Based on the scientific advice from French Health Authority (ANSM), the protocol is amended to add a new exclusion criterion, add a pregnancy testing control at the safety follow-up visit, and provide clarity that the patient has the option at the end of the study to join a planned long-term study. Based on comments from the French Ethics Committee exclusion criterion E23 has been removed.",
        "effectiveDate": "2020-02-06",
        "reasonIds": [
          "ar_4_1",
          "ar_4_2",
          "ar_4_3"
        ],
        "previousVersion": "Amended Clinical Trial Protocol 01",
        "newVersion": "1 (electronic 2.0)"
      },
      {
        "id": "amend_5",
        "number": "1",
        "name": "Amendment 1",
        "scope": {
          "id": "17cd9aae-99ca-424e-8e2a-b91e18a15729",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "c7080266-afe2-479a-9ea3-0d148609761a",
          "code": {
            "id": "cb11230f-2f9d-4e75-ae53-1b6d05475896",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "c60fee26-0f16-4aee-8618-91c4b1c0c476",
            "type": {
              "id": "f4615a0b-e9d1-4160-b3cf-73b8542aa382",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "Based on the final results of the repeat dose study and in alignment with scientific advice from Health Authorities, the protocol is amended to modify the dose regimen, efficacy endpoint analysis pertaining to an intra-patient comparison, and the safety endpoint of 'the occurrence of vascular thrombotic events'.",
        "effectiveDate": "2019-08-28",
        "reasonIds": [
          "ar_5_1",
          "ar_5_2",
          "ar_5_3"
        ],
        "previousVersion": "Original Protocol",
        "newVersion": "1 (electronic 1.0)"
      }
    ],
    "amendmentReasons": [
      {
        "id": "ar_1_1",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_2",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_3",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_1",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_2",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_3",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_3_1",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_1",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_2",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_3",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_5_1",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_5_2",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_5_3",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      }
    ],
    "countries": [
      {
        "id": "country_1",
        "name": "United States",
        "instanceType": "Country",
        "code": "US"
      },
      {
        "id": "country_2",
        "name": "France",
        "instanceType": "Country",
        "code": "FR"
      },
      {
        "id": "country_3",
        "name": "Italy",
        "instanceType": "Country",
        "code": "IT"
      }
    ],
    "studySites": [],
    "summary": {
      "amendmentCount": 5,
      "countryCount": 3,
      "siteCount": 0
    },
    "geographicScope": {
      "id": "geo_1",
      "name": "Study Geographic Scope",
      "scopeType": "Global",
      "instanceType": "GeographicScope",
      "countryIds": [
        "country_1",
        "country_2",
        "country_3"
      ],
      "regions": [
        "North America",
        "Europe"
      ]
    }
  },
  "rawResponse": {
    "amendments": [
      {
        "number": "5",
        "effectiveDate": "2021-08-20",
        "summary": "The protocol is amended with the following main changes: Addition of statistical testing for some secondary efficacy endpoints; Addition of an exit interview for participants from selected countries.",
        "previousVersion": "Amended Clinical Trial Protocol 04",
        "newVersion": "1 (electronic 7.0)",
        "reasons": [
          "Scientific",
          "Operational",
          "Administrative"
        ]
      },
      {
        "number": "4",
        "effectiveDate": "2020-05-13",
        "summary": "The main reasons for this amendment are the following: to modify the requirements for the washout of FVIII products before screening and allow inclusion of patients based on historical FVIII results or documented genotype known to produce severe hemophilia A; to allow for flexibility in the washout of FVIII products before the Baseline visit in patients participating in the abbreviated PK group; to allow for faster infusion rate for the BIVV001 injection performed at home; to clarify that in case of minor surgery the FVIII activity and the BIVV001 dosing at the 24h follow up will be performed only if clinically warranted; to clarify the reporting of overdoses; to clarify that during study visits, for reliable PK assessment, PK sampling should not be done via the same intravenous access route as used for the BIVV001 administration.",
        "previousVersion": "Amended Clinical Trial Protocol 03",
        "newVersion": "1 (electronic 5.0)",
        "reasons": [
          "Operational",
          "Scientific",
          "Administrative"
        ]
      },
      {
        "number": "3",
        "effectiveDate": "2020-04-06",
        "summary": "Based on the request from Italy Competent Authority (AIFA) the protocol is amended to update an exclusion criterion related to renal function, as well as to add additional assessments for height and physical examination.",
        "previousVersion": "Amended Clinical Trial Protocol 02",
        "newVersion": "1 (electronic 4.0)",
        "reasons": [
          "Regulatory"
        ]
      },
      {
        "number": "2",
        "effectiveDate": "2020-02-06",
        "summary": "Based on the scientific advice from French Health Authority (ANSM), the protocol is amended to add a new exclusion criterion, add a pregnancy testing control at the safety follow-up visit, and provide clarity that the patient has the option at the end of the study to join a planned long-term study. Based on comments from the French Ethics Committee exclusion criterion E23 has been removed.",
        "previousVersion": "Amended Clinical Trial Protocol 01",
        "newVersion": "1 (electronic 2.0)",
        "reasons": [
          "Regulatory",
          "Safety",
          "Scientific"
        ]
      },
      {
        "number": "1",
        "effectiveDate": "2019-08-28",
        "summary": "Based on the final results of the repeat dose study and in alignment with scientific advice from Health Authorities, the protocol is amended to modify the dose regimen, efficacy endpoint analysis pertaining to an intra-patient comparison, and the safety endpoint of 'the occurrence of vascular thrombotic events'.",
        "previousVersion": "Original Protocol",
        "newVersion": "1 (electronic 1.0)",
        "reasons": [
          "Scientific",
          "Regulatory",
          "Safety"
        ]
      }
    ],
    "geographicScope": {
      "type": "Global",
      "countries": [
        {
          "name": "United States",
          "code": "US"
        },
        {
          "name": "France",
          "code": "FR"
        },
        {
          "name": "Italy",
          "code": "IT"
        }
      ],
      "regions": [
        "North America",
        "Europe"
      ],
      "plannedSites": null
    },
    "sites": []
  }
}